Literature DB >> 19028275

Radiotherapy for early-stage Hodgkin's lymphoma: a 21st century perspective and review of multiple randomized clinical trials.

Voichita Bar Ad1, Ora Paltiel, Eli Glatstein.   

Abstract

The treatment of Hodgkin's lymphoma has improved dramatically over the past decades. Over the last half century, Hodgkin's lymphoma has become one of the most curable cancers of adulthood. More than 90% of the patients with localized stages of the disease can be cured with modern treatment strategies. Long-term toxicities are now the major concern for survivors of early-stage disease. Contemporary therapeutic approaches for Hodgkin's lymphoma attempt to preserve the high cure rate achieved, while reducing treatment-related acute and late toxicities. The aim of this review is to re-examine the historical and the current role of radiotherapy for early-stage Hodgkin's lymphoma, given the latest evidence of an increasing role of chemotherapy for the treatment of this malignancy. The literature search was performed in PubMed Plus. Studies on children were excluded.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028275     DOI: 10.1016/j.ijrobp.2008.08.026

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  Old but new methods in radiation oncology.

Authors:  Keisuke Sasai
Journal:  Int J Clin Oncol       Date:  2013-04-24       Impact factor: 3.402

2.  Cardiac MRI for Detecting Early Cardiac Toxicity after Proton Therapy for Hodgkin Lymphoma.

Authors:  James E Bates; Christopher Klassen; Savas Ozdemir; Stella Flampouri; Robert Percy; Nancy P Mendenhall; Bradford S Hoppe
Journal:  Int J Part Ther       Date:  2019-05-07

3.  Radiotherapy for patients with stage IV classical Hodgkin lymphoma: a propensity-matched analysis of the surveillance, epidemiology, and end results database.

Authors:  Shijie Wang; Mingfang Jia; Jianglong Han; Rui Zhang; Kejie Huang; Ping Li; Qin Li; Yunfeng Qiao; Qibin Song; Zhenming Fu
Journal:  Cancer Biol Ther       Date:  2020-08-23       Impact factor: 4.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.